
Charles River Laboratories International CRL
$ 157.49
-0.32%
Annual report 2025
added 02-18-2026
Charles River Laboratories International Total Shareholders Equity 2011-2026 | CRL
Annual Total Shareholders Equity Charles River Laboratories International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.16 B | 3.46 B | 3.6 B | 2.98 B | 2.54 B | 2.12 B | 1.63 B | 1.32 B | 1.05 B | 837 M | 733 M | 672 M | 641 M | 601 M | 526 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.6 B | 526 M | 1.72 B |
Quarterly Total Shareholders Equity Charles River Laboratories International
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.41 B | 3.35 B | 3.19 B | 3.46 B | 3.79 B | 3.73 B | 3.65 B | 3.6 B | 3.31 B | 3.26 B | 3.11 B | 2.98 B | 2.63 B | 2.65 B | 2.61 B | 2.53 B | 2.43 B | 2.32 B | 2.18 B | 2.11 B | 2.11 B | 2.11 B | 2.11 B | 1.63 B | 1.63 B | 1.63 B | 1.63 B | 1.32 B | 1.32 B | 1.32 B | 1.32 B | 1.05 B | 1.05 B | 1.05 B | 1.05 B | 837 M | 837 M | 837 M | 837 M | 733 M | 733 M | 733 M | 733 M | 672 M | 672 M | 672 M | 672 M | 641 M | 641 M | 641 M | 641 M | 601 M | 601 M | 601 M | 601 M | 526 M | 526 M | 526 M | 526 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.79 B | 526 M | 1.67 B |
Total Shareholders Equity of other stocks in the Diagnostics research industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Agilent Technologies
A
|
5.39 B | $ 112.78 | 0.68 % | $ 34.3 B | ||
|
Centogene N.V.
CNTG
|
27.5 M | - | -6.23 % | $ 30.6 M | ||
|
Biomerica
BMRA
|
4.1 M | $ 2.13 | - | $ 4.89 M | ||
|
Fulgent Genetics
FLGT
|
1.13 B | $ 16.31 | -0.12 % | $ 493 M | ||
|
Akumin
AKU
|
-48.2 M | - | -17.87 % | $ 25.9 M | ||
|
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | ||
|
Lantheus Holdings
LNTH
|
1.09 B | $ 74.22 | -1.99 % | $ 5.01 B | ||
|
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M | ||
|
Medpace Holdings
MEDP
|
459 M | $ 457.05 | 0.03 % | $ 13.2 B | ||
|
Mettler-Toledo International
MTD
|
-23.6 M | $ 1 242.53 | 0.28 % | $ 25.6 B | ||
|
Myriad Genetics
MYGN
|
368 M | $ 4.59 | -1.61 % | $ 425 M | ||
|
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | ||
|
Aspira Women's Health
AWH
|
6.73 M | - | -6.19 % | $ 10.5 M | ||
|
Pacific Biosciences of California
PACB
|
5.35 M | $ 1.37 | -1.8 % | $ 411 M | ||
|
Co-Diagnostics
CODX
|
86 M | $ 4.4 | 101.83 % | $ 129 M | ||
|
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
1.69 B | - | 0.12 % | $ 80.1 M | ||
|
Precipio
PRPO
|
14.4 M | $ 26.85 | -0.3 % | $ 34.8 M | ||
|
Personalis
PSNL
|
203 M | $ 7.51 | -1.38 % | $ 445 M | ||
|
RadNet
RDNT
|
1.09 B | $ 59.53 | -3.58 % | $ 4.48 B | ||
|
IQVIA Holdings
IQV
|
6.5 B | $ 164.98 | -1.19 % | $ 28.4 B | ||
|
Senseonics Holdings
SENS
|
61 M | $ 6.58 | -0.6 % | $ 275 M | ||
|
Sotera Health Company
SHC
|
606 M | $ 13.78 | -0.76 % | $ 3.91 B | ||
|
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | ||
|
Invitae Corporation
NVTA
|
102 M | - | - | $ 21.2 M | ||
|
BioNano Genomics
BNGO
|
44.4 M | $ 1.21 | -17.47 % | $ 6.59 M | ||
|
National Research Corporation
NRC
|
14 M | $ 17.47 | -0.26 % | $ 391 M | ||
|
Neuronetics
STIM
|
22.4 M | $ 1.54 | -4.06 % | $ 102 M | ||
|
Interpace Biosciences
IDXG
|
-2.22 M | $ 1.71 | 0.73 % | $ 7.5 M | ||
|
IDEXX Laboratories
IDXX
|
1.61 B | $ 572.18 | -1.09 % | $ 46 B | ||
|
Illumina
ILMN
|
2.37 B | $ 124.58 | 0.64 % | $ 19.8 B | ||
|
ICON Public Limited Company
ICLR
|
9.52 B | $ 99.8 | -0.55 % | $ 8.23 B | ||
|
Guardant Health
GH
|
-99.3 M | $ 82.96 | -2.36 % | $ 10.4 B | ||
|
QIAGEN N.V.
QGEN
|
3.57 B | - | - | $ 10.6 B | ||
|
Twist Bioscience Corporation
TWST
|
473 M | $ 44.3 | -0.45 % | $ 2.65 B | ||
|
Celcuity
CELC
|
116 M | $ 100.81 | -5.57 % | $ 3.98 B | ||
|
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
8.62 B | $ 263.8 | -0.23 % | $ 21.9 B | ||
|
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | ||
|
ENDRA Life Sciences
NDRA
|
2.56 M | $ 3.41 | -2.16 % | $ 1.83 M | ||
|
NeoGenomics
NEO
|
837 M | $ 7.9 | -2.47 % | $ 1.01 B | ||
|
Natera
NTRA
|
706 M | $ 194.02 | -3.03 % | $ 19.1 B | ||
|
CareDx, Inc
CDNA
|
303 M | $ 17.35 | -1.2 % | $ 925 M | ||
|
OPKO Health
OPK
|
1.37 B | $ 1.14 | -1.3 % | $ 791 M |